anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The safety and effectiveness of BRIDION for reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide have been established in pediatric patients aged 2 years and older. Use of BRIDION in these age groups is supported by evidence from an adequate and well-controlled study of BRIDION [see Clinical Pharmacology (12.3) and Clinical Studies (14.1)]. In pediatric patients aged 2 years and older, the safety profile is generally consistent with that observed in adults [see Adverse Reactions (6.1)].

Safety and effectiveness in patients younger than 2 years of age have not been established.

Juvenile Animal Studies

In a bone deposition study, sugammadex concentrations were significantly higher in juvenile rats compared to adult rats (13% vs. 3% of the administered dose, respectively) following a single intravenous (IV) dose at 30 mg/kg (0.3 times the MRHD based on adult AUC comparison).

In a juvenile animal bone toxicity study, 7-day old rats were dosed intravenously once daily for 28 days with 0, 30, 120, and 500 mg/kg sugammadex (approximately 0.1, 0.6, and 3 times the MRHD, respectively, by adult AUC comparison). Sugammadex at 120 and 500 mg/kg decreased ulna and femur bone lengths by approximately 3%, which did not recover after an 8-week treatment-free period. Reversible whitish discoloration and disturbance of enamel formation were also observed in the incisors at these dose levels. In molars, this effect was only observed at 500 mg/kg. The no-observed-effect-level (NOEL) was 30 mg/kg.

In a second juvenile animal bone toxicity study, 7-day old rats were dosed once weekly for 8 weeks with 0, 7.5, 30, and 120 mg/kg (up to 1.2 times the MRHD of 16 mg/kg based on adult AUC comparison). No adverse effects on bone or teeth were noted.
Systems and methods for the oral administration of a therapy are disclosed. For example, the therapy can treat symptoms of gastro-esophageal reflux disease (GERD) by providing a medicinal agent to the esophagus and mouth to counter acidic reflux. In one embodiment, the agent includes an antacid. In another embodiment, the agent comprises a salivant. Also, an antacid and salivant may be employed together. The active agents may be further combined with other ingredients, including materials that foster slow release of the active ingredients, as well as coatings and flavorings. The active agents may be provided in the form of a tablet or as granules. The active agents can be positioned in the buccal area; i.e., between the upper gum and the cheek, and particularly within close proximity to the outlet of the parotid saliva duct. An appliance that positions the active agents in the mouth is also provided.
Three randomized, double-blind, active-controlled studies were designed to evaluate effectiveness of SEPTOCAINE containing epinephrine 1:100,000 as a dental anesthetic. Patients ranging in age from 4 years to over 65 years old underwent simple dental procedures such as single uncomplicated extractions, routine operative procedures, single apical resections, and single crown procedures, or complex dental procedures such as multiple extractions, multiple crowns and/or bridge procedures, multiple apical resections, alveolectomies, muco-gingival operations, and other surgical procedures on the bone. SEPTOCAINE containing epinephrine 1:100,000 was administered by intraoral submucosal infiltration or nerve block for these dental procedures. 

Efficacy was measured immediately following the procedure by having the patient and investigator rate the patient's procedural pain using a 10 cm visual analog scale (VAS), in which a score of zero represented no pain and a score of 10 represented the worst pain imaginable. Mean patient and investigator VAS pain scores were 0.3-0.4 cm for simple procedures and 0.5-0.6 cm for complex procedures.

Four randomized, double-blind, active-controlled studies were performed comparing SEPTOCAINE containing epinephrine 1:100,000 versus SEPTOCAINE containing epinephrine 1:200,000. The first two studies used electric pulp testers (EPT) to evaluate the success rate (maximum EPT value within 10 minutes), onset, and duration of SEPTOCAINE containing epinephrine 1:100,000 versus SEPTOCAINE containing epinephrine 1:200,000 and articaine solution without epinephrine in healthy adults between 18 and 65 years old. Results indicated that the anesthetic characteristics of the 1:100,000 and 1:200,000 formulations are not significantly different.

A third study compared the difference in visualization of the surgical field after administration of SEPTOCAINE containing epinephrine 1:100,000 versus SEPTOCAINE containing epinephrine 1:200,000 during bilateral maxillary periodontal surgeries in patients ranging from 21 to 65 years old. SEPTOCAINE containing epinephrine 1:100,000 provided better visualization of the surgical field and less blood loss during the procedures. In a fourth study, designed to assess and compare cardiovascular safety, when the maximum dose of each formulation was administered, no clinically relevant differences in blood pressure or heart rate between formulations were observed.
OBJECTIVES: Monoacylglycerol lipase (MAGL) is a cytosolic serine hydrolase considered a potential novel drug target for the treatment of CNS disorders including epilepsy. Here we examined MAGL levels in a rat model of epilepsy.
METHODS: Autoradiography has been used to validate the binding properties of the MAGL radiotracer, [3H]T-401, in the rat brain, and to explore spatial and temporal changes in binding levels in a model of temporal lobe epilepsy model using unilateral intra-hippocampal injections of kainic acid (KA) in rats.
RESULTS: Specific and saturable binding of [3H]T-401 was detected in both cortical grey and subcortical white matter. Saturation experiments revealed a KD in the range between 15 nM and 17 nM, and full saturation was achieved at concentrations around 30 nM. The binding could be completely blocked with the cold ligand (Ki 44.2 nM) and at higher affinity (Ki 1.27 nM) with another structurally different MAGL inhibitor, ABD 1970. Bilateral reduction in [3H]T-401 binding was observed in the cerebral cortex and the hippocampus few days after status epilepticus that further declined to a level of around 30% compared to the control. No change in binding was observed in either the hypothalamus nor the white matter at any time point. Direct comparison to [3H]UCB-J binding to synaptic vesicle glycoprotein 2 A (SV2A), another protein localized in the pre-synapse, revealed that while binding to MAGL remained low in the chronic phase, SV2A was increased significantly in some cortical areas.
SIGNIFICANCE: These data show that MAGL is reduced in the cerebral cortex and hippocampus in a chronic epilepsy model and indicate that MAGL inhibitors may further reduce MAGL activity in the treatment resistant epilepsy patient.
Bladder oversensitivity and detrusor overactivity are two important diagnosis of urodynamic study regarding storage function of bladder. Between November 2010 and October 2020, all women with ≥ stage II cystocele who visited the urogynecological department of a medical center for cystocele repair were reviewed. Those women who had complete data of preoperative and postoperative 3-month follow-up urodynamic data were excluded from this study. Bladder oversensitivity was diagnosed if the volume of strong desire was less than 300mL. Detrusor overactivity was defined as the occurrence of involuntary detrusor contractions during filling cytometry.

STATA software was used for statistical analysis. Chi2 test, univariate and multivariable logistic regression tests were used for statistical analysis as appropriate. A p \< 0.05 was considered as statistically significant.
This study will evaluate effectiveness of two problem-solving training interventions on caregivers' emotional health and well-being (stress, depressive symptoms, caregiving self-efficacy). Participants are family members of patients with acquired brain injuries (ABI) admitted for inpatient rehabilitation, with a planned discharge home. Caregivers who agree to participate will be randomly assigned to one of three family support interventions. The Building Better Caregiver program is a peer-led group intervention. Problem Solving Training is an individual clinician-led intervention. Both interventions aim to equip caregivers with problem solving tools. The third intervention is existing support and assistance for family members who will be caregivers for patients discharged home after inpatient rehabilitation. This Usual Care is available to all three groups and consists of nurse instruction in care routines, case management family support for discharge, referral to family counseling and community services as indicated, and general information resources about brain injury.

Caregiver-reported outcome measures (CROs) will be collected in three domains: 1) caregiver stress/burden and emotional health, 2) caregiver perceived self-efficacy in managing their loved-one's care needs, and 3) healthcare utilization by patient and caregiver. We will use three standardized outcome measures: 1) Kingston Caregiver Stress Scale (KCSS), 2) Patient Health Questionnaire (PHQ-9), and 3) Revised Scale for Caregiving Self-Efficacy (SCS-E). The measures will be collected at four timepoints: upon enrollment in the study ("Pre"), within 72 hours of discharge (D/C), and 30 and 90 days post-discharge. The impact of each intervention on the rate of patients' 30-day, unplanned hospital readmissions will also be examined.
Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or negatively charged therapeutic agent and a charged molecule of opposite charge for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5  mu m and 30  mu m, which together yield an aerodynamic diameter of the particles of between approximately one and three microns. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of poly(lactic acid) or poly(glycolic acid) or copolymers thereof. Alternatively, the particles may be formed solely of a therapeutic or diagnostic agent and a surfactant. Surfactants can be incorporated on the particle surface for example by coating the particle after particle formation, or by incorporating the surfactant in the material forming the particle prior to formation of the particle. Exemplary surfactants include phosphoglycerides such as dipalmitoyl phosphatidylcholine (DPPC). The particles can be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide a variety of therapeutic agents. Formation of complexes of positively or negatively charged therapeutic agents with molecules of opposite charge can allow control of the release rate of the agents into the blood stream following administration.
Spatially Resolved Transcriptomics (SRT) serves as a cornerstone in biomedical research, revealing the heterogeneity of tissue microenvironments. Integrating multimodal data including gene expression, spatial coordinates, and morphological information poses significant challenges for accurate spatial domain identification. Herein, we present the Multi-view Contrastive Graph Autoencoder (MCGAE), a cutting-edge deep computational framework specifically designed for the intricate analysis of spatial transcriptomics (ST) data. MCGAE advances the field by creating multi-view representations from gene expression and spatial adjacency matrices. Utilizing modular modeling, contrastive graph convolutional networks, and attention mechanisms, it generates modality-specific spatial representations and integrates them into a unified embedding. This integration process is further enriched by the inclusion of morphological image features, markedly enhancing the framework's capability to process multimodal data. Applied to both simulated and real SRT datasets, MCGAE demonstrates superior performance in spatial domain detection, data denoising, trajectory inference, and 3D feature extraction, outperforming existing methods. Specifically, in colorectal cancer liver metastases, MCGAE integrates histological and gene expression data to identify tumor invasion regions and characterize cellular molecular regulation. This breakthrough extends ST analysis and offers new tools for cancer and complex disease research.
BACKGROUND: There are limited data on the efficacy of targeted therapy in metastatic osteosarcoma. The goal of this study was to assess the effectiveness of sorafenib in adult patients with heavily pretreated metastatic osteosarcoma.
METHOD: Patients with metastatic osteosarcoma aged more than 18 years were assessed retrospectively. The patients' clinical, pathological, and therapeutic data were collected. For survival analysis, Kaplan-Meier models were used.
RESULTS: The research involved 15 patients. The ratio of male and female patients was 2/1, with a median age of 25 years (range: 19-64 years). The most common primary tumor localization was the extremities (66.6%). Fourteen (93.3%) patients had previously received palliative chemotherapy and six (40%) patients had palliative radiotherapy. The median progression-free survival was found as 5.5 months (95% confidence interval, 1.3-9.7). A stable response was observed in seven (46.6%) patients and progressive disease in eight (53.4%) patients. Grade 1-2 toxicities were detected in 50% of the patients, while grade 3-4 toxicities were observed in 14.3% of the patients.
CONCLUSIONS: We demonstrated real-life results of sorafenib for disease management in pretreated adult patients with metastatic osteosarcoma in the study. Sorafenib was effective for disease control and well tolerated in the patients. Sorafenib may be a treatment option for disease control after the disease progresses with chemotherapy in patients with metastatic osteosarcoma.
The invention provides compositions and methods for inhibiting Chk1 and/or Chk2 kinases. Also provided are compositions and methods for inhibiting G2 cell arrest checkpoint, particularly in mammalian, e.g. human cells. The compositions and methods of the invention are also used to treat disorders of cell growth, such as cancer. In particular, the invention provides methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA damaging agents and treatments. Also provided are methods for screening for compounds able to interact with, e.g., inhibit, enzymes involved in the G2 cell cycle arrest checkpoint, such as Chk1 and/or Chk2/Cds1 kinase.
The Western diet is common in the United States and has a lot of salt, sugar, and fat. Modern globalization has shifted eating habits in many countries toward this unhealthy Western diet. For example, U.S. cable TV in other countries promotes this Western diet through advertisements for junk foods and sugary drinks. This is a major concern because experimental research studies show that seeing food advertising while watching TV leads to eating more food afterwards. Research studies also show that people who watch a lot of TV tend to think that junk food is not that harmful.

Researchers now believe that some people living outside the U.S. are drawn to the U.S. culture and lifestyle and can become "Americanized" through a process called remote acculturation. These Americanized people in other countries such as Jamaica are mostly teenagers, but sometimes also adults. Americanized people outside the United States are even more likely to adopt the unhealthy Western diet even though they have never lived in the United States. In research the investigators did before getting this grant, they showed that Americanized youth and mothers in Jamaica watched more hours of U.S. cable daily and also ate more unhealthy food. This led them to develop a new healthy eating education program for Americanized families in Jamaica that highlighted the role of U.S. media - the "J(amaican) U(nited) S(tates) Media? Programme". The JUS Media? Programme teaches young people and mothers to question the health messages in food advertising on U.S. cable TV so that they can be smarter and healthier consumers. For example, the JUS Media? Programme covers the recommended food guidelines in Jamaica and teaches adolescents and their mothers the principles of media literacy, such as to think about "who is the source of this message?" "what do they want you to do?" and "what information is missing?". Finally, the JUS Media? Programme teaches participants to use these media literacy principles to challenge unhealthy food advertisements by creating smart, funny parody versions called subvertisements.

In this project,the investigators evaluated how well the JUS Media? Programme worked for 7th graders and their mothers in Jamaica. About 30 adolescents and their mothers got a 2-session workshop, another 30 families got the workshop and text messages, and another 30 families did not get any part of the program.
Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of 1% lidocaine.
Dispense in the original sealed carton with the enclosed Instructions for Use.

Prior to first use, XULTOPHY 100/3.6 should be stored between 2°C and 8°C (36°F to 46°F) until the expiration date printed on the label. Store prefilled pens in the carton so they will stay clean and protected from light. Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze. Do not use XULTOPHY 100/3.6 if it has been frozen. 

After first use, the XULTOPHY 100/3.6 pen can be stored for 21 days at controlled room temperature (59°F to 86°F; 15°C to 30°C) or in a refrigerator (36°F to 46°F; 2°C to 8°C). Keep all XULTOPHY 100/3.6 pens away from direct heat and light. 

Always remove the needle after each injection and store the XULTOPHY 100/3.6 pen without a needle attached. This prevents contamination and/or infection, or leakage of the XULTOPHY 100/3.6 pen, and will ensure accurate dosing. Always use a new needle for each injection to prevent contamination.

The storage conditions are summarized in Table 11:

Table 11: Storage Conditions for XULTOPHY 100/3.6 Pen
Cefadroxil monohydrate should be used with caution in the presence of markedly impaired renal function (creatinine clearance rate of less than 50 mL/min/1.73 M2). (See DOSAGE AND ADMINISTRATION.) In patients with known or suspected renal impairment, careful clinical observation and appropriate laboratory studies should be made prior to and during therapy.

Prescribing cefadroxil for oral suspension in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Prolonged use of cefadroxil monohydrate may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Cefadroxil monohydrate should be prescribed with caution in individuals with history of gastrointestinal disease, particularly colitis.
### Adults

The recommended dosage of undiluted OMNIPAQUE 350 at a concentration of 350 mg Iodine/mL for oral pass-thru examination of the gastrointestinal tract in adults is 50 mL to 100 mL depending on the nature of the examination and the size of the patient. The recommended oral dosage of OMNIPAQUE diluted to concentrations of 6 mg Iodine/mL to 9 mg Iodine/mL for contrast enhanced computed tomography of the abdomen in adults is 500 mL to 1000 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). In conjunction with dilute oral administration, the recommended dosage of OMNIPAQUE 300 intravenously is 100 mL to 150 mL. The oral dose is administered about 20 to 40 minutes prior to the intravenous dose and image acquisition.

### Pediatric Patients

The dosage of undiluted OMNIPAQUE 300 at a concentration of 300 mg Iodine/mL, is dependent on the nature of the examination and the size of the patient. Based on clinical experience, it is recommended that OMNIPAQUE 180 (available in single use vials), be used in pediatric patients less than 3 months of age. OMNIPAQUE 300 may be used in pediatric patients 3 months of age and older.

The following dosage guidelines are recommended:

When given rectally, larger volumes may be used.

The recommended oral dosage of OMNIPAQUE diluted to concentrations of 9 mg Iodine/mL to 21 mg Iodine/mL for contrast computed tomography of the abdomen in pediatric patients is 180 mL to 750 mL. Smaller administered volumes are needed as the concentration of the final solution is increased (see Table below). The total oral dose in grams of iodine should generally not exceed 5 g Iodine for pediatric patients under 3 years of age and 10 g Iodine for pediatric patients from 3 to 18 years of age. The oral dosage may be given all at once or over a period of 30 to 45 minutes if there is difficulty in consuming the required volume. In conjunction with dilute oral administration the recommended dosage of OMNIPAQUE 300 is 2mL/kg when administered intravenously with a range of 1 mL/kg to 2 mL/kg. Dosage pediatric patients should be administered in proportion to age and body weight. The total intravenously administered dose should not exceed 3 mL/kg. The oral dose is administered about 30 to 60 minutes prior to the intravenous dose and image acquisition.

OMNIPAQUE may be diluted with water or beverage as follows:

Dilutions of OMNIPAQUE should be prepared just prior to use and any unused portion discarded after the procedure.
PROBLEM TO BE SOLVED: To obtain the subject external preparation capable of improving stability of retinoids and maintaining the effectiveness of product for a long period of time by including a retinoid, a vitamin E and an amino sugar as essential components. SOLUTION: This skin preparation comprises (A) a retinoid (a compound showing vitamin A activity, the generic name of a compound working finally in an organism as a retinoic acid composite linked to a binding protein, such as various isomers of retinoic acid, etc.), (B) a vitamin E (the generic name of various compounds 2-methyl-6-chromanol structure having essential qualities as a radical scavenger such as α-tocopherol, etc.), and (C) an amino sugar (the generic name of a monosaccharide having a structure of formula I, formula II or formula III, a polysaccharide, a glycolipid, etc., and their derivatives such as glycosaminoglycan, etc.), as essential components. Preferably the amount of the composition A is, in the case of retinoic acid, 0.0001-2 wt.%, that of the component B is 0.001-10 wt.% and that of that of the component C is 0.001-20 wt.% based on the skin preparation.